频繁使用阿司匹林与卵巢癌风险关联的修正:基于两个卵巢癌联盟个体水平数据的Meta分析
该Meta分析整合17项研究的个体水平数据(队列研究2600例,病例对照研究5726例),评估频繁使用阿司匹林(≥6天/周)与卵巢癌风险的关联及效应修正。结果显示频繁使用阿司匹林与卵巢癌风险降低13%(95%CI 6-20)相关,除子宫内膜异位症亚组外,各风险因素亚组均观察到一致的風險降低,包括≥2个风险因素者(RR 0.81,95%CI 0.73-0.90)。
要点
- 频繁使用阿司匹林(≥6天/周)与卵巢癌风险降低13%相关(95%CI 6-20)。
- 研究设计异质性无统计学意义(P=0.48),组织学类型异质性无统计学意义(P=0.60)。
- 除子宫内膜异位症外,其他风险因素亚组均观察到风险降低(RR范围0.79-0.93)。
核心结论
- 频繁使用阿司匹林与较低的卵巢癌风险相关,无论是否存在大多数其他卵巢癌风险因素。
- 在具有多个风险因素的女性中也观察到风险降低,为频繁使用阿司匹林的化学预防项目可针对更高风险亚组提供了原理验证。
研究设计与样本
- 研究纳入卵巢癌队列联盟的9项队列研究(2600例病例)和卵巢癌协会联盟的8项病例对照研究(5726例病例)。
- 使用Cox回归和logistic回归评估各研究内频繁使用阿司匹林(≥6天/周)与卵巢癌风险的关联,并采用随机效应Meta分析合并研究特异性估计值。
- 按个体卵巢癌风险因素(子宫内膜异位症、肥胖、乳腺癌/卵巢癌家族史、未产、口服避孕药使用、输卵管结扎)及风险因素数量(0、1、≥2个)进行亚组分析。
主要发现
- 总体而言,频繁使用阿司匹林与卵巢癌风险降低13%相关(95%CI 6-20)。
- 研究设计异质性无统计学意义(P=0.48),组织学类型异质性无统计学意义(P=0.60)。
- 在子宫内膜异位症女性中未观察到关联。
- 在其他所有按卵巢癌风险因素定义的亚组中均观察到一致的风险降低(相对风险范围0.79至0.93,所有异质性P>0.05)。
- 在≥2个风险因素的女性中,相对风险为0.81(95%CI 0.73-0.90)。
关键数值与推荐
- 频繁使用阿司匹林定义为≥6天/周。
- 总体卵巢癌风险降低13%(95%CI 6-20)。
- ≥2个风险因素女性的相对风险为0.81(95%CI 0.73-0.90)。
- 其他风险因素亚组的相对风险范围为0.79至0.93,所有异质性P>0.05。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Frequent aspirin use has been associated with reduced ovarian cancer risk, but no study has comprehensively assessed for effect modification. We leveraged harmonized, individual-level data from 17 studies to examine the association between frequent aspirin use and ovarian cancer risk, overall and across subgroups of women with other ovarian cancer risk factors. METHODS: Nine cohort studies from the Ovarian Cancer Cohort Consortium (n = 2,600 cases) and eight case-control studies from the Ovarian Cancer Association Consortium (n = 5,726 cases) were included. We used Cox regression and logistic regression to assess study-specific associations between frequent aspirin use (≥ 6 days/week) and ovarian cancer risk and combined study-specific estimates using random-effects meta-analysis. We conducted analyses within subgroups defined by individual ovarian cancer risk factors (endometriosis, obesity, family history of breast/ovarian cancer, nulliparity, oral contraceptive use, and tubal ligation) and by number of risk factors (0, 1, and ≥ 2). RESULTS: Overall, frequent aspirin use was associated with a 13% reduction in ovarian cancer risk (95% CI, 6 to 20), with no significant heterogeneity by study design (P = .48) or histotype (P = .60). Although no association was observed among women with endometriosis, consistent risk reductions were observed among all other subgroups defined by ovarian cancer risk factors (relative risks ranging from 0.79 to 0.93, all P-heterogeneity > .05), including women with ≥ 2 risk factors (relative risk, 0.81; 95% CI, 0.73 to 0.90). CONCLUSION: This study, the largest to-date on aspirin use and ovarian cancer, provides evidence that frequent aspirin use is associated with lower ovarian cancer risk regardless of the presence of most other ovarian cancer risk factors. Risk reductions were also observed among women with multiple risk factors, providing proof of principle that chemoprevention programs with frequent aspirin use could target higher-risk subgroups.
引用
- Hurwitz LM, Townsend MK, Jordan SJ, et al. Modification of the Association Between Frequent Aspirin Use and Ovarian Cancer Risk: A Meta-Analysis Using Individual-Level Data From Two Ovarian Cancer Consortia. J Clin Oncol. 2022. PMID: 35867953. doi:10.1200/JCO.21.01900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。